SPCG-13 试验最终生存结果:中高危前列腺癌根治性放疗后辅助多西他赛对比监测
SPCG-13 试验评估中高危前列腺癌根治性放疗联合雄激素剥夺治疗后,六周期辅助多西他赛对比监测的生存获益。5 年生化复发无生存差异(主要终点)。10 年计划次要终点分析显示,辅助多西他赛组 10 年总生存率估计为 77.4%,监测组为 66.8%,但 Kaplan-Meier 生存曲线无显著差异(log-rank p=0.154)。
要点
- 辅助多西他赛组 10 年总生存率估计 77.4%,监测组 66.8%,但差异无统计学意义。
- 高 Gleason 评分患者总生存更差(HR 1.925,95%CI 1.213-3.053;p=0.005)。
- 调整 Gleason 评分后,辅助多西他赛对比监测的总生存 HR 为 0.776(95%CI 0.508-1.187;p=0.242)。
核心结论
- 辅助多西他赛与 10 年总生存的轻微改善相关,但未达统计学显著性,尤其在高 Gleason 评分组。
研究设计与样本
- SPCG-13 随机试验的 10 年生存分析,纳入 233 例有更新总生存和无转移生存数据的患者,为计划次要终点。
主要发现
- 监测组中位总生存为 14.5 年,辅助多西他赛组未达到。
- Kaplan-Meier 生存曲线在两组间随时间无显著差异(log-rank 检验 p=0.154)。
- 10 年总生存率估计:辅助多西他赛组 77.4%,监测组 66.8%。
- Cox 回归显示高 Gleason 评分患者总生存更差(HR 1.925,95%CI 1.213-3.053;p=0.005)。
- 调整 Gleason 评分风险后,辅助多西他赛对比监测的总生存 HR 为 0.776(95%CI 0.508-1.187;p=0.242)。
关键数值与推荐
- 主要终点 5 年生化复发无生存在监测组与辅助多西他赛组间无差异。
- 10 年总生存率估计:辅助多西他赛组 77.4%,监测组 66.8%。
- 高 Gleason 评分与更差总生存相关(HR 1.925,95%CI 1.213-3.053;p=0.005)。
临床怎么用
- 中高危局限性前列腺癌根治性放疗及雄激素剥夺治疗后,辅助多西他赛未显著提高 10 年总生存。
- 高 Gleason 评分患者生存更差,可充分讨论化疗获益与风险后考虑多西他赛。
- 该人群仍需进一步试验探索治疗选择。
局限性
- 10 年生存分析基于 233 例有更新数据的患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The SPCG-13 trial investigated whether six cycles of adjuvant docetaxel (aDoc) improves survival in patients with intermediate- or high-risk prostate cancer after radical curative radiotherapy and androgen deprivation therapy. There was no difference in biochemical recurrence-free survival (primary endpoint) at 5-yr between the surveillance (SV) and aDoc arms. Here we report 10-yr survival data (planned secondary endpoint). Updated overall survival (OS) and metastasis-free survival data were available for 233 patients. There were no demographic differences between the original randomized cohort and the 10-yr survival population. Thus, this 10-yr sample is deemed representative of the original patient population. Median OS was 14.5 yr in the SV and was not reached in the aDoc arm. No significant difference in Kaplan-Meier survival emerged between the arms over time (log-rank test p = 0.154). Estimates of the 10-yr OS rate favored aDoc (77.4% vs 66.8%). Cox regression analysis revealed a trend towards worse OS for patients with a high Gleason score (GS; hazard ratio [HR] 1.925, 95% confidence interval [CI] 1.213-3.053; p = 0.005). A Cox model adjusted for GS risk revealed an OS HR of 0.776 (95% CI 0.508-1.187; p = 0.242) for aDoc versus SV. In conclusion, aDoc was associated with a slight, but not statistically significant, improvement in 10-yr OS, especially in the high-GS group. PATIENT SUMMARY: Our 10-year survival analysis for the SPCG-13 trial showed that six cycles of chemotherapy with docetaxel after radiotherapy and androgen deprivation therapy for intermediate- or high-risk localized prostate cancer did not significantly increase survival. Survival was worse for cancers with a high Gleason score, so docetaxel could be considered after a careful discussion of the benefits and harms of chemotherapy. Further trials are needed to investigate options for this group of patients.
引用
- Kellokumpu-Lehtinen PL, Fransson AS, Marttila T, et al. Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial. Eur Urol Oncol. 2025. PMID: 40312180. doi:10.1016/j.euo.2025.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。